{'52WeekChange': 0.94000006,
 'SandP52WeekChange': None,
 'address1': '3201 Carnegie Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.81,
 'askSize': 1200,
 'averageDailyVolume10Day': 3139525,
 'averageVolume': 4417704,
 'averageVolume10days': 3139525,
 'beta': -1.714285,
 'beta3Year': None,
 'bid': 2.78,
 'bidSize': 2200,
 'bookValue': 0.111,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cleveland',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.89,
 'dayLow': 2.73,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -10.987,
 'enterpriseToRevenue': 124.046,
 'enterpriseValue': 519503424,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '216-361-9495',
 'fiftyDayAverage': 2.7834287,
 'fiftyTwoWeekHigh': 4.38,
 'fiftyTwoWeekLow': 1.13,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 177774082,
 'forwardEps': -0.4,
 'forwardPE': -7.0249996,
 'fromCurrency': None,
 'fullTimeEmployees': 83,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.0925,
 'heldPercentInstitutions': 0.16654,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1181001600,
 'lastSplitFactor': '0:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/athersys.com',
 'longBusinessSummary': 'Athersys, Inc., a biotechnology company, focuses on '
                        'the research and development activities in the field '
                        'of regenerative medicine. Its clinical development '
                        'programs are focused on treating neurological '
                        'conditions, cardiovascular diseases, inflammatory and '
                        'immune disorders, and pulmonary and other conditions. '
                        "The company's lead platform product includes "
                        'MultiStem cell therapy, an allogeneic stem cell '
                        'product, which is in Phase III clinical study for the '
                        'treatment of patients suffering from neurological '
                        'damage from an ischemic stroke, as well as in Phase '
                        'II clinical study for the treatment of patients with '
                        'acute myocardial infarction, and has completed Phase '
                        'I clinical study for the treatment of patients '
                        'suffering from leukemia or various other blood-borne '
                        'cancers. It also develops MultiStem cell therapy to '
                        'promote tissue repair and healing for animal '
                        'patients, including those suffering from serious '
                        'conditions with unmet medical needs. The company has '
                        'license and collaboration agreements with Healios '
                        'K.K. to develop and commercialize MultiStem cell '
                        'therapy for ischemic stroke, acute respiratory '
                        'distress syndrome, and ophthalmological indications, '
                        'as well as for the treatment of liver, kidney, '
                        'pancreas, and intestinal tissue diseases; and the '
                        'University of Minnesota to develop MultiStem cell '
                        'therapy platform. Athersys, Inc. was founded in 1995 '
                        'and is headquartered in Cleveland, Ohio.',
 'longName': 'Athersys, Inc.',
 'market': 'us_market',
 'marketCap': 552965824,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_25192',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -47270000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.87,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.31,
 'phone': '216-431-9900',
 'previousClose': 2.91,
 'priceHint': 4,
 'priceToBook': 25.315315,
 'priceToSalesTrailing12Months': 132.03578,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.89,
 'regularMarketDayLow': 2.73,
 'regularMarketOpen': 2.87,
 'regularMarketPreviousClose': 2.91,
 'regularMarketPrice': 2.87,
 'regularMarketVolume': 2658332,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 196784992,
 'sharesPercentSharesOut': 0.12,
 'sharesShort': 23604578,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 11726254,
 'shortName': 'Athersys, Inc.',
 'shortPercentOfFloat': 0.133,
 'shortRatio': 3.92,
 'startDate': None,
 'state': 'OH',
 'strikePrice': None,
 'symbol': 'ATHX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.303,
 'twoHundredDayAverage': 2.2076259,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '652ff454-b29b-3086-a883-e6205eef7413',
 'volume': 2658332,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.athersys.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '44115'}